Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers

Journal of Clinical Psychopharmacology

Volumn 21, Issue 3, 2001, Pages 330-334

  Eap, Chin B ^a   Bondolfi, Guido ^b   Zullino, Daniele ^a   Savary Cosendai, Line ^a   Powell Golay, Kerry ^a   Kosel, Markus ^a   Baumann, Pierre ^a  

^a Hopital de Cery   (Switzerland)

^b Hôpital Belle Idèe   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; FLUOXETINE; NORFLUOXETINE; RISPERIDONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DEPRESSION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG METABOLISM; ENANTIOMER; FEMALE; GENOTYPE; HUMAN; MALE; PRIORITY JOURNAL; STEREOCHEMISTRY;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYTOCHROME P-450 CYP2D6; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FLUOXETINE; HUMANS; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; STATISTICS, NONPARAMETRIC; STEREOISOMERISM;

EID: 0035018421     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200106000-00013     Document Type: Article

References (17)

1. Altamura AC, Moro AR, Percudani M. Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet 1994;26:201-14.
2. Wong DT, Bymaster FP, Reid LR, et al. Norfluoxetine enantiomers as inhibitors of serotonin uptake in rat brain. Neuropsychopharmacology 1993;8:337-44.
3. Kroemer HK, Eichelbaum M. It's the gene, stupid - molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci 1995;56:2285-98.
4. Hamelin BA, Turgeon J, Vallée F, et al. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin Pharmacol Ther 1996;60:512-21.
5. Fjordside L, Jeppesen U, Eap CB, et al. The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine. Pharmacogenetics 1999;9:55-60.
6. Eap CB, Gaillard N, Powell K, et al. Simultaneous determination of plasma levels of fluvoxamine and of the enantiomers of fluoxetine and norfluoxetine by gas-chromatography-mass spectrometry. J Chromatogr Biomed Appl 1996;682:265-72.
7. Heim M, Meyer UA. Genotyping of poor metabolisers of debrisoquine by allele-speciflc PCR amplification. Lancet 1990;336:529-32.
8. Griese E-U, Zanger UM, Brudermanns U, et al. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 1998;8: 15-26.
9. Heykants J, Huang M-L, Mannens G, et al. The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry 1994;55 [suppl 5]:13-7.
10. Fang J. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol 1999;359:147-51.
11. Ekins S, Bravi G, Binkley S, et al. Three and four dimensional-quantitative structure activity relationship (3D-QSAR) analyses of CYP2D6 inhibitors. Pharmacogenetics 1999;9:477-89.
12. Ketter TA, Flockhart DA, Post RM, et al. The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol 1995;15:387-98.
13. von Moltke LL, Greenblatt DJ, Duan SX, et al. Human cytochromes mediating N-demethylation of fluoxetine in vitro. Psychopharmacology (Berl) 1997; 132:402-7.
14. Amsterdam JD, Fawcett J, Quitkin FM, et al. Fluoxetine and nor-fluoxetine plasma concentrations in major depression: a multi-center study. Am J Psychiatry 1997; 154:963-9.
15. Kasper S, Höflich G, Scholl H-P, et al. Safety and antidepressant efficacy of selective serotonin re-uptake inhibitors. Hum Psychopharmacol 1994:9:1-12.
16. Stevens JC, Wrighton SA. Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450. J Pharmacol Exp Ther 1993;266:964-71.
17. Margolis JM, O'Donnell JP, Mankowski DC, et al. (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab Dispos 2000;28:1187-91.